When the Basics Outperform the Blockbusters

If you've been carefully timing your morning protein to protect muscle as you age, a new meta-analysis of seven trials has some humbling news: it made no meaningful difference to lean mass, grip strength, or leg strength in adults over 60 [1]. The more exciting muscle news is elsewhere — B vitamins slowed brain atrophy by 24% in people with early cognitive decline [2], and a 16-week dietary coaching program helped athletes gain 4.28 kg of lean mass without changing their training load at all [3].

People with mental health conditions are hospitalized for malnutrition at a rate nearly 8 times higher than the general population — and they rack up over 11 times more bed-days — even after excluding eating disorders from the count [1]. That's a group representing about 3% of residents accounting for 14% of all malnutrition-related admissions. If brain health and nutrition still feel like separate domains, that number should change your mind.

When obese women with endometrial cancer needed to lose weight to protect their remission, a plain lifestyle program quietly outperformed both a trendy GLP-1 drug and bariatric surgery: the structured diet-and-exercise approach delivered 85% complete tumor remission at two years, versus 74% for semaglutide and 60% for sleeve gastrectomy [1]. Even more striking, the surgical group showed the highest rate of weight regain (67%) by year two — suggesting that for these patients, slower and steadier really does win the race.

Of all the findings here, the gestational diabetes data is the one that should change clinical practice: a glucose test taken in the first days after delivery looked reassuring in all but 1 out of 201 women — yet by the 12-week follow-up, nearly a quarter to nearly a third of those same women already had prediabetes or diabetes. That early normal reading isn't a green light; it's a false one. The biology of glucose recovery after pregnancy plays out over weeks, not days, and the window that actually catches trouble is the one many women skip.

More than half of American adults aren't getting enough magnesium from their diet — and new trial data make that feel a lot more urgent than a nutrition label footnote. Supplementation cut migraine attack frequency from 16% to 42%, meaningfully lowered blood sugar markers in people with type 2 diabetes over 24 weeks, and nearly quadrupled the response rate for chronic constipation. It's one of the cleaner examples in recent research of a very common gap with specific, measurable fixes.

Your gut bacteria might affect how jaundiced your newborn becomes — a Mendelian randomization study found that one gut microbe, Adlercreutzia, was associated with a staggering 686% increase in neonatal jaundice risk, while another genus, Slackia, was linked to an 82% reduction [1]. These findings hint that the microbiome — possibly maternal, possibly the infant's own early colonization — may be shaping outcomes we've long blamed entirely on other factors. The gut keeps turning up in the most unexpected places.

Fewer than 1% of Australian pregnant women met recommended daily servings for even three food groups — despite most saying they were actively trying to eat well [1]. Meanwhile in pediatric ICUs, a counterintuitive finding holds up: sometimes not feeding critically ill kids intravenously right away leads to better outcomes [2]. Early life nutrition is full of surprises this month.

The most eye-catching number from this research cycle: a four-week swap from meat to mycoprotein — the fungus-derived protein behind products like Quorn — cut LDL cholesterol by 10%, blood glucose by 13%, and a key insulin demand marker by 27%. A sweeping review of next-generation food technologies concludes that mycoprotein and biofortification (adding nutrients directly into crops at the farm) are currently the only approaches backed by solid human-trial evidence [1]. Lab-grown meat, by contrast, still costs around $63 per kilogram — more than twelve times the $5/kg target needed to compete commercially — and its greenhouse gas advantage over beef could actually flip negative if production continues to rely on fossil-fuel electricity.

Combining a NAD+-pathway drug with simply cutting dietary nicotinic acid — a common form of vitamin B3 — didn't just slow small-cell lung cancer in lab models, it eliminated tumors outright, outperforming standard cisplatin/etoposide chemotherapy in most tested models. The main side effect was a temporary, reversible dip in white blood cells. If even a fraction of this holds up in people, it would be one of the more striking examples of a dietary tweak turning a modest drug into something far more potent.